In moments when markets fixate on fear and surface-level metrics, the deeper question of what a business actually generates — and whether the world has priced that fairly — often goes unasked. Three Indian industrial companies, spanning mining consumables, specialty chemicals, and petroleum refining, are each trading at valuations that appear expensive by conventional measures, yet reveal a different picture when examined through the lens of cash flow. The gap between perception and underlying generation is where patient capital has historically found its footing.